Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

STATUS

Recruiting
End date

Mar 12, 2023
participants needed

25
sponsor

University of Washington

Send

Updated on 16 May 2022

See if I qualify

cancer

measurable disease

direct bilirubin

gilbert's syndrome

testosterone

metastasis

neutrophil count

liver metastasis

tumor cells

abiraterone

enzalutamide

testosterone level

serum testosterone

adenocarcinoma

adenocarcinoma of prostate

Summary

This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testosterone can cause the growth of prostate cancer cells. Abiraterone acetate lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Enzalutamide blocks the use of testosterone by the tumor cells. Giving erdafitinib with abiraterone acetate or enzalutamide may work better in treating patients with prostate cancer compared to abiraterone acetate or enzalutamide alone.

Description

OUTLINE: Patients receive abiraterone acetate orally (PO) once daily (QD) or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Details

Condition	Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Treatment	Enzalutamide, abiraterone acetate, Erdafitinib
Clinical Study Identifier	NCT03999515
Sponsor	University of Washington
Last Modified on	16 May 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	History of histologically diagnosed prostatic adenocarcinoma
	Participants must have evidence of castration resistant prostate cancer as evidenced by a confirmed rising PSA or radiographic progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate serum testosterone level (i.e. =< 50 mg/dL)
	Participants must have previously progressed on abiraterone acetate and/or enzalutamide, with PSA or radiographic progression on the most recent agent per PCWG3 criteria. If the most recent agent received was abiraterone or enzalutamide there should be no washout prior to initiating erdafitinib per protocol
	Measurable disease as defined per RECIST v1.1 criteria
	Subjects must have evidence of double-negative prostate cancer as defined by immunohistochemistry on biopsy. A fresh metastatic biopsy within 8 weeks is preferred; however, any archival tissue showing a DNPC phenotype will be acceptable for determining eligibility. Note: transcript profiling methods for defining DNPC may be accepted per the PI's discretion
	Eastern Cooperative Oncology Group (ECOG) performance status score =< 2
	Hemoglobin >= 8 g/dL (>= 5 mmol/L) (must be without red blood cell [RBC] transfusion within 7 days prior to the laboratory test)
	Platelets >= 75 x 10^9/L
	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (prior growth factor support is permitted but must be without support in the 7 days prior to the laboratory test)
	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN for subjects with liver metastases
	Creatinine clearance >= 40 mL/min/1.73 m^2 based upon modified diet in renal disease formula calculation
	Total bilirubin =< 1.5 x ULN; except in subjects with congenital bilirubinemia, such as Gilbert syndrome
	Corrected QT interval (corrected QT interval by Fridericia [QTcF] or QT corrected interval by the Bazett's formula [QTcB]) =< 480 msec based on the average of triplicate assessments performed approximately 5 minutes apart
	Subjects must agree to use acceptable contraception
	Must sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Exclusion Criteria
	Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to randomization
	Active malignancies (i.e., requiring treatment change in the last 24 months) other than malignancy under study (except skin cancers within the last 24 months that is considered completely cured)
	Evidence of predominant small cell or neuroendocrine variant prostate cancer on most recent standard of care metastatic biopsy
	Symptomatic central nervous system (CNS) metastases. Treated CNS metastases will be allowed if these are stable for at least 8 weeks prior to enrollment
	Received prior FGFR inhibitor treatment or if the subject has known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
	Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade
	Has persistent phosphate level > ULN during screening (on 2 consecutive assessments at least 1 week apart, within 14 days of treatment and prior to cycle 1 day 1) and despite medical management
	Has a history of or current uncontrolled cardiovascular disease including
	Unstable angina, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cardiac arrest, or known congestive heart failure class III-V within the preceding 3 months; cerebrovascular accident or transient ischemic attack within the preceding 3 months
	Pulmonary embolism or other VTE (venous thromboembolism) within the preceding 2 months
	Has known active acquired immune deficiency syndrome (AIDS) (human immunodeficiency
	virus [HIV] infection)
	Hepatitis B infection as defined according to the American Society of Clinical Oncology guidelines. In the event the infection status is unclear, quantitative levels are necessary to determine the infection status. Hepatitis C (anti-hepatitis C virus [HCV] antibody positive or HCV-ribonucleic acid [RNA] quantitation positive) or known to have a history of hepatitis C. If positive, further testing of quantitative levels to rule out positivity is required
	Has not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, hot flashes, grade 1 neuropathy, grade 1-2 hearing loss)
	Has impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
	Major surgery within 2 weeks of the first dose, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration. (Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate
	Any serious underlying medical condition, such as
	Evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection
	Active autoimmune disease or a documented history of autoimmune disease
	Psychiatric conditions (e.g., alcohol or drug abuse), dementia, or altered mental status
	Patient, who, in the opinion of their treating physician, requires immediate treatment (e.g. those with extensive liver metastases)
	Any other issue that would impair the ability of the subject to receive or tolerate
	the planned treatment at the investigational site, to understand informed
	consent or any condition for which, in the opinion of the investigator
	participation would not be in the best interest of the subject (e.g
	compromise the well-being) or that could prevent, limit, or confound the
	protocol-specified assessments

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

adenocarcinoma of prostate

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer